Autran B, Carcelain G, Li T S,et al. Positive effects of combined antiretroviral therapy on CD4+T cellhomeostasis and function in ad-vanced HIV disease [J]. Science, 1997, 277(5322): 112.
Pavel Bostik S,Noble Susan T,Stephenson,et al. CD4+T cells from simian immunodeficiency virus disease-resistant sooty mangabeys produce more IL-2 than cells from disease-susceptible species: involvement of p300 and CREB at the proximal IL-2 promoter in IL-2 up-regulation[J]. J Immunol, 2007,178:7720.
[12]
Marchetti G, T\'incati C, Monforte A, et al. The challenge of IL-2 immunotherapy in HIV disease:"no through road" or turning point? [J]. Curr HIV Res,2008, 6(3):189.
[13]
Marchetti G, Meroni L, Molteni C,et al.Interleukin-2 immuotherapy exerts a differential effect on CD4 and CD8 T cell dynamics[J].AIDS,2004,18(2):211.
[14]
Smith K A.Low-dose daily interleukin-2 immunotherapy:accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity[J].AIDS,2001,15:S28.
[15]
Fry T J, Mackall C L.The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance[J].J Immunol, 2005, 174(11): 6571.
[16]
Lodolce J P, Burkett P R, Koka R M,et al.Regulation of lymphoid homeostasis by interleukin-15 [J].Cytok Growth Fac Rev, 2002, 13(6): 429.
[17]
Ahmad A, Atunad R, lannello A, et al. IL-15 and HIV infection:lesson for immunotherapy and vaccination[J].Curr HIV Res,2005, 3(3):261.
[18]
Laura Adalid-Peralta,Veronique Godot,Celine Colin, et al. Stimulation of the primary anti-HIV antibody response by IFIV-a in patients with acute HIV-1 infection[J]. J Leukocyte Biol,2008,83:1060.
[19]
Dhillon R, Rossi S, Herrine S K. Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients[J]. Ther Clin Risk Manag,2008, 4(4):789.
[20]
Tuma P, Yispo E, Barreiro P, et al. Role of tenofovir in HIV and hepatitis C virus coinfection[J]. Enferm Infecc Microbiol Clin,2008, 26(Suppl 8):31.
[21]
Streeck H, Frahm N, Walker B D. The role of IFN-gamma elispot assay in HIV vaccine research[J]. Nat Protoc,2009,4(4):461.
[22]
Kinloch-De, Loes S.Role of therapeutic vaccines in the control of HIV-1[J].J Antimicrob Chemother,2004,53(4):562.
[23]
Tsoukas C M, Tuner H M, Hatzakis G E, et al. Improvement of HIV-specific immunity in HIV infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells[J]. AIDS Res Hum Retro, 2001, 17:887.
Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation[J]. N Engl J Med,2009, 360(7):724.
[28]
Douek D C,McFarland R D,Keiser P H,et al.Changes in thymic function with age and during the treatment of HIV in fection[J]. Nature,1998,396( 6712): 690.
[29]
Senior K. HE2000 AIDS drug shows promise in clinical trials[J]. Mol Med Today,2000,6(9):333.
Fernandez-Cruz E,Navarro J, Rodriguez-Sainz C,et al.The potential role of the HIV-1 immunogen(Remune(R)) as a therapeutic vaccine in the treatment of HIV infection[J].Expert Rev Vaccines,2003,2(6):739.
